<DOC>
	<DOCNO>NCT01732796</DOCNO>
	<brief_summary>The aim study confirm efficacy treatment 16 24 week chronically infect HCV GT1b treatment naïve patient , include patient compensated cirrhosis .</brief_summary>
	<brief_title>IFN-free Combination Therapy HCV-infected Patients Treatment-naive : HCVerso1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : Chronic hepatitis C infection , diagnose positive HCV Ab detectable HCV RNA screen addition least one following : 1. positive HCV RNA HCV antibody least 6 month prior screen , 2. liver biopsy typical chronic hepatitis C , 3. history elevate ALT least 6 month prior screen . HCV infection subGT1b confirm genotypic test screen Treatment naïve define : 1. prior treatment interferon , pegylated interferon , /or ribavirin 2. prior treatment least one dose license investigational antiviral agent acute chronic hepatitis C infection Plasma HCV RNA &gt; = 1,000 IU/mL screen Liver biopsy within three year fibroscan within six month prior randomization . Patients compensate liver cirrhosis ( score ChildPugh A ) could also include . Age 18 75 year Female patient negative urine pregnancy test ( dipstick ) Visit 2 prior randomization 1. documented hysterectomy , 2. ovary remove , 3. document tubal ligation , 4. postmenopausal last menstrual period least 12 month prior screen , 5. childbearing potential negative serum pregnancy test screen negative urine pregnancy test Day 1 ( Visit 2 ) , agree use two nonhormonal method birth control date screen month last dose ribavirin . They must breastfeed time date screen 7 month last dose ribavirin . Medically accept method contraception females trial diaphragm spermicide substance , intrauterine device , cervical cap condom . OR : Male patient 1. document sterile , 2. consistently correctly use condom female partner ( childbearing potential ) agree use one appropriate medically accept method birth control date screen 7 month last dose ribavirin , 3. without pregnant female partner . It responsibility male patient ensure partner ( partner ) pregnant prior enrolment study become pregnant treatment followup phase . Female partner childbearing potential must perform monthly pregnancy test date screen 7 month last dose ribavirin ( test provide sponsor ) . Exclusion criterion : HCV infection mixed genotype ( 1/2 , 1/3 , 1/4 ) diagnose genotypic test screening . HCV subtype 1a , mix 1a/1b GT1 undefined Evidence liver disease mainly due cause chronic HCV infection autoimmune hepatitis , primary biliary cirrhosis , hemochromatosis Wilson 's disease HIV1 HIV2 infection Hepatitis B virus ( HBV ) infection base presence HBsAg Evidence decompensated liver disease , history decompensated liver disease , define history ascites , hepatic encephalopathy , bleed esophageal varix , International Normalized Ratio ( INR ) &gt; =1.7 Serum albumin &lt; 3.3 g/dL Serum total bilirubin &gt; 2.0 time upper limit normal ( ULN ) direct/indirect ratio &gt; 1 , unless history Gilbert 's disease Active suspect malignancy history malignancy within last 5 year ( exception appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix ) Patients ongoing historical photosensitivity recurrent rash</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>